The Influence of CYP2D6 Phenotype on the Pharmacokinetic Profile of Atomoxetine in Caucasian Healthy Subjects

1. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391-99.10.1093/ajhp/61.22.239115581262Search in Google Scholar

2. B Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9.10.1136/adc.2004.059386176527015665154Search in Google Scholar

3. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571-90.10.2165/00003088-200544060-0000215910008Search in Google Scholar

4. Findling RL. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review. Clin Ther. 2008;30(5):942-57.10.1016/j.clinthera.2008.05.00618555941Search in Google Scholar

5. Yu G, Li G-F, Markowitz JS. Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016;26(x):1-13.10.1089/cap.2015.0137487652926859445Search in Google Scholar

6. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002;30(3):319-23.10.1124/dmd.30.3.31911854152Search in Google Scholar

7. Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attentiondeficit hyperactivity disorder 1. 2004;18(6):397-401.Search in Google Scholar

8. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003;31(1):98-107.10.1124/dmd.31.1.9812485958Search in Google Scholar

9. Matsui A, Azuma J, Witcher JW, et al. Pharmacokinetics, safety and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. J Clin Pharmacol. 2012;52(3):388-403.10.1177/009127001139865721543662Search in Google Scholar

10. Cui YM, Teng CH, Pan AX, et al. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Br J Clin Pharmacol. Wiley-Blackwell; 2007;64(4):445-49.Search in Google Scholar

11. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17(2):93-101.10.1097/01.fpc.0000239974.69464.f217301689Search in Google Scholar

12. Zhou S-F. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Clin Pharmacokinet. 2009;48(11):689-723.10.2165/11318030-000000000-0000019817501Search in Google Scholar

13. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13.10.1038/sj.tpj.650028515492763Search in Google Scholar

14. Brown JT, Bishop JR. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Pharmacogenomics. 2015;16(13):1513-20.10.2217/PGS.15.9326314574Search in Google Scholar

15. LLerena A, Naranjo MEG, Rodrigues-Soares F, Penas-LLedo EM, Farinas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 2014;10(11):1569-83.10.1517/17425255.2014.96420425316321Search in Google Scholar

16. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(1):23-37.10.1007/s00210-003-0832-214618296Search in Google Scholar

17. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521-90.10.1124/pr.58.3.616968950Search in Google Scholar

18. Belle DJ, Ernest CS, Sauer J-M, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42(11):1219-27.10.1177/00912700276249130712412820Search in Google Scholar

19. Shah RR, Smith RL. Addressing phenoconversion: The Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015;79(2):222-40.10.1111/bcp.12441430962924913012Search in Google Scholar

20. Abraham BK, Adithan C. Genetic Polymorphism of Cyp2D6. Indian J Pharmacol. 2001;33(2):147-69.Search in Google Scholar

21. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet. 2012;27(1):55-67.10.2133/dmpk.DMPK-11-RV-121Search in Google Scholar

22. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol. 2007;63(4):321-33.10.1007/s00228-006-0250-817273835Search in Google Scholar

23. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol. 1985;25(4):296-301.10.1002/j.1552-4604.1985.tb02842.x4008676Search in Google Scholar

24. Wang B, Yang L-P, Zhang X-Z, Huang S-Q, Bartlam M, Zhou S-F. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41(4):573-643.10.1080/0360253090311872919645588Search in Google Scholar

25. Pan X, Jeong H. Estrogen-induced cholestasis leads to repressed CYP2D6 expression in CYP2D6-humanized mice. Mol Pharmacol. 2015;88(1):106-12.10.1124/mol.115.098822446864025943116Search in Google Scholar

26. F Fijal BA, Guo Y, Li SG, et al. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. J Clin Pharmacol. 2015;55(10):1167-74.10.1002/jcph.53025919121Search in Google Scholar

27. Michelson D, Read H, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46(2):242-51.10.1097/01.chi.0000246056.83791.b617242628Search in Google Scholar

28. Wanwimolruk S, Prachayasittikul V, Phopin K, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). Excli J. 2014;13:347-91.Search in Google Scholar

29. Wanwimolruk S, Phopin K, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). Excli J. 2014;13:869-96.Search in Google Scholar